BSW Wealth Partners Takes $450,000 Position in Sanofi (NASDAQ:SNY)

BSW Wealth Partners bought a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,113 shares of the company's stock, valued at approximately $450,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in SNY. Brighton Jones LLC grew its position in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. IFP Advisors Inc boosted its stake in shares of Sanofi by 17.2% in the 4th quarter. IFP Advisors Inc now owns 2,132 shares of the company's stock valued at $103,000 after purchasing an additional 313 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of Sanofi in the 4th quarter valued at approximately $76,000. NewEdge Wealth LLC grew its holdings in shares of Sanofi by 20.5% during the 4th quarter. NewEdge Wealth LLC now owns 32,799 shares of the company's stock valued at $1,582,000 after purchasing an additional 5,591 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. increased its position in Sanofi by 1.0% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 126,811 shares of the company's stock worth $6,116,000 after purchasing an additional 1,216 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SNY. Morgan Stanley set a $56.00 price target on shares of Sanofi in a report on Monday, June 2nd. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $61.50.

Sanofi Trading Up 1.3%

Shares of NASDAQ SNY traded up $0.62 during midday trading on Monday, reaching $48.47. The stock had a trading volume of 292,762 shares, compared to its average volume of 2,631,222. The company's 50 day moving average price is $50.95 and its 200 day moving average price is $52.06. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The firm has a market cap of $118.87 billion, a price-to-earnings ratio of 17.33, a price-to-earnings-growth ratio of 0.99 and a beta of 0.50.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. Sanofi's quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.78 earnings per share. As a group, sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were paid a $2.0369 dividend. This represents a dividend yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. Sanofi's payout ratio is currently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.